SynopsisIdhifa is a drug used to treat relapsed or refractory acute myeloid leukemia in people with specific mutations of the isocitrate dehydrogenase 2 (IDH2) gene, determined by an FDA-approved IDH2 companion diagnostic test The global Idhifa market size is ex.....
SynopsisGemtuzumab ozogamicin is a drug-linked monoclonal antibody (an antibody-drug conjugate) that was used to treat acute myeloid leukemia from 2000 to 2010. The global Gemtuzumab Ozogamicin market size is expected to reach US$ 179.5 million by 2029, growing .....
SynopsisGemtuzumab ozogamicin is a drug-linked monoclonal antibody (an antibody-drug conjugate) that was used to treat acute myeloid leukemia from 2000 to 2010. The global Gemtuzumab Ozogamicin Drugs market size is expected to reach US$ 179.5 million by 2029, gr.....
SynopsisMylotarg is a drug-linked monoclonal antibody (an antibody-drug conjugate) that was used to treat acute myeloid leukemia from 2000 to 2010. The global Mylotarg market size is expected to reach US$ 179.5 million by 2029, growing at a CAGR of -2.5% from 20.....
SynopsisMidostaurin is a multi-targeted protein kinase inhibitor that has been investigated for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and advanced systemic mastocytosis. The global Midostaurin market size is expected to re.....
SynopsisMidostaurin is a multi-targeted protein kinase inhibitor that has been investigated for the treatment of acute myeloid leukemia (AML), myelodysplastic syndrome (MDS) and advanced systemic mastocytosis. The global Midostaurin Drugs market size is expected.....
SynopsisIvosidenib is an experimental drug for treatment of cancer. It is a small molecule inhibitor of IDH1, which is mutated in several forms of cancer. The global Ivosidenib market size is expected to reach US$ 238.5 million by 2029, growing at a CAGR of 4.8%.....
SynopsisIvosidenib is an experimental drug for treatment of cancer. It is a small molecule inhibitor of IDH1, which is mutated in several forms of cancer. The global Ivosidenib Drugs market size is expected to reach US$ 238.5 million by 2029, growing at a CAGR o.....
SynopsisTibsovo is an experimental drug for treatment of cancer. It is a small molecule inhibitor of IDH1, which is mutated in several forms of cancer. The global Tibsovo market size is expected to reach US$ 238.5 million by 2029, growing at a CAGR of 4.8% from .....
SynopsisVYXEOS is a liposomal combination of daunorubicin, an anthracycline topoisomerase inhibitor, and cytarabine, The global Cytarabine and Daunorubicin market size is expected to reach US$ 184 million by 2029, growing at a CAGR of 5.3% from 2023 to 2029. The.....
